Vir and GSK start Phase 2/3 trial for experimental COVID-19 treatment

/ / News

Shares of Vir Biotechnology Inc. gained 9.2% in premarket trading on Monday when the company and GlaxoSmithKline said they had begun dosing patients in the Phase 2/3 clinical study for their experimental COVID-19 antibody treatment. GSK’s stock was up 0.2%. This double-blind, placebo-controlled trial is testing whether their investigational treatment can prevent hospitalization; it will enroll around 1,300 COVID-19 patients. The companies said they expect to have interim results by the end of the year and complete findings from the trial in the first quarter of next year. Since the start of the year, Vir’s stock has rallied 231.1%, shares of GSK are down 16.7%, and the S&P 500 is up 8.5%.

hylactic T cell vaccine.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.